Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44
Conclusion: We developed a CD44-specific scFv-Fc construct that binds with nanomolar affinity to human CD44. When radiolabeled with 64Cu or 89Zr, it demonstrated specific uptake in CD44-expressing MDA-MB-231 tumors. The high tumor uptake (~56% injected dose/g) warrants clinical investigation of [89Zr]Zr-DFO-scFv-Fc-CD44 as a versatile PET imaging agent for patients with CD44-positive tumors.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Diebolder, P., Mpoy, C., Scott, J., Huynh, T. T., Fields, R., Spitzer, D., Bandara, N., Rogers, B. E. Tags: Basic Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Nanotechnology | Nuclear Medicine | Stem Cell Therapy | Stem Cells | Study